ArticleEJNMMI research2018
First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02111954 (PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- First-in-human radiation dosimetry of the GRPR antagonist [EJNMMI research · 2026Article
- The Impact of the Injected Mass of the Gastrin-Releasing Peptide Receptor Antagonist on Uptake in Breast Cancer: Lessons from a Phase I Trial of [Pharmaceutics · 2025Article
- A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibody.CPT: pharmacometrics & systems pharmacology · 2025Article
- 2-[Molecular imaging and biology · 2025Article
- Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer.Annals of medicine · 2024Review
- Dosimetry of [medRxiv : the preprint server for health sciences · 2024Article
- Biodistribution and radiation dosimetry of [EJNMMI research · 2024Article
- A prospective comparative study of [European journal of nuclear medicine and molecular imaging · 2023Article
- Biodistribution, Dosimetry, and Pharmacokinetics ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- GRPR-targeting radiotheranostics for breast cancer management.Frontiers in medicine · 2023Review
- Imaging Properties and Tumor Targeting ofBiomedicines · 2022Article
- Radiolabeled Bombesin Analogs.Cancers · 2021Review
- GRPr AntagonistJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.Journal of clinical medicine · 2021Review
- Human biodistribution and dosimetry of [EJNMMI physics · 2021Article
- Effect of the versatile bifunctional chelator AAZTAEJNMMI radiopharmacy and chemistry · 2020Article
- Radiation dosimetry ofEJNMMI research · 2020Article
- First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [European journal of nuclear medicine and molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrin-releasing peptide receptor antagonists have promise in theranostics of several highly incident tumours, including prostate and breast. This study presents the first human dosimetry of
resultsThe body regions receiving the highest absorbed doses were the pancreas, the urinary bladder wall, the small intestine and the kidneys (260, 69.8, 38.8 and 34.8 μGy/MBq respectively). The ED considering a 30-min urinary voiding cycle was 17.6 μSv/MBq in male patients. The increment of voiding time interval produced a significant increase of absorbed doses in bladder, prostate and testes, as well as an increase of ED. ED also increased if calculated with OLINDA/EXM 1.1. These results have been discussed in view of similar publications on bombesin analogues or on other commonly used theranostic peptides.
conclusionsThe pancreas is the most irradiated organ after the injection of
trial registrationClinicaltrial.Gov identifier: NCT02111954 , posted on 11/042014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.